PROKIDNEY CORP. JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - PROKIDNEY CORP
Explicit Guidance:
- Clinical Milestones: Enrollment expected to finish in Q1 2027; accelerated approval readout on surrogate endpoint (eGFR slope) anticipated in Q2 2027; BLA filing expected in Q1 2028; confirmatory data set (time-to-composite events) targeted for second half of 2029.
- Study Assumptions: Phase III powered to detect a 1.5 mL/min/year difference in eGFR decline (sham group assumed 3.0 mL/min decline); confirmatory trial powered for a hazard ratio of 0.6, assuming an event rate of 10–12 per 100 patient-years.
- Manufacturing Capacity: Initial launch capacity of 350 doses annually; capacity expansion to 500 doses expected ~12 months post-launch; long-term target of 3,000 doses within a few years.
- Pricing Context: Implicit pricing strategy targeting $400,000–$500,000 annual cost based on comparable cell therapies and IgAN treatments, justified by potential system savings of $200,000 per patient-year (avoiding dialysis).
Business-Segment Outlook:
- Product Strategy: Single product focus on RuparinCell (autologous cell therapy) for patients with advanced diabetic chronic kidney disease (stage 3b/4) on standard of care.
- Market Opportunity: Targets a sub-segment of the ~1 million US patients with advanced CKD who continue to progress despite standard therapies; potential for a "substantial market" despite not being a chronic therapy (1–2 injections).
- Patient Demographics: Focus on patients with multiple comorbidities (average 8–12 daily medications) and high residual risk of kidney-related or cardiovascular events.
Market and Competitive Outlook:
- Competitive Landscape: Differentiates from chronic daily therapies (SGLT2, GLP-1, ACEi, ARBs, MRAs) by offering a one-time/one-two-dose intervention for patients failing current standards.
- Treatment Gap: Positioned to address residual risk in patients who progress despite existing "four pillars" of therapeutic options.
- Regulatory Path: Utilizing RMAT designation; targeting accelerated approval based on surrogate endpoint (eGFR slope) followed by confirmatory endpoint (time to composite events).
Macro / Industry Outlook:
- Economic Value: Highlights significant economic burden of dialysis ($100k+/year for Medicare, 2x+ for private payers), creating value for payers who prevent progression.
- Global Cost Context: Notes that dialysis costs vary globally, with some European countries paying more than the US; emphasizes societal impact beyond direct payer costs (lost productivity, caregiver burden).
- Regulatory Environment: Anticipated interaction with FDA regarding BLA submission timelines driven by recruitment surges and manufacturing validation requirements.
Strategic Initiatives:
- Manufacturing Expansion: Construction of an adjacent manufacturing facility (500 dose capacity) nearing completion; expansion into additional rooms for future scaling; potential for CDMO partnerships or geographic expansion to reach 3,000 dose capacity.
- Product Development: Transitioned from fresh to cryopreserved product for Phase II (007) and Phase III to ensure consistency; ongoing work on tech transfer for expanded facility.
- Capital Requirements: Management acknowledges need for additional investment (dilutive, debt, or partnerships) to scale manufacturing and treat the broader population if the product succeeds.
Risks and Headwinds to Outlook:
- Execution Risks: BLA filing timeline pushed to Q1 2028 (from earlier expectations) due to increased recruitment demand requiring full enrollment of eligible patients and delayed manufacturing site modifications/validations.
- Clinical Risks: Potential for bleeding or infection complications related to kidney biopsy; risk that confirmatory event rates (10–12 per 100 patient-years) may differ from global assumptions if US patient population trends vary.
- Adoption Risks: Need to secure payer reimbursement at pricing levels comparable to other cell therapies ($400k–$500k) to achieve substantial sales.
- Data Release Strategy: Management intends to withhold detailed confirmatory data until the full endpoint is met to "avoid burning alpha" prematurely.
Management Tone on the Future:
- Confidence: Expresses "high confidence" that eGFR slope data in Q2 2027 will translate to event benefits in the confirmatory readout due to the high correlation of eGFR declines with composite events.
- Focus: Emphasizes "single purpose" and avoiding distraction from the immediate goal of advanced diabetic CKD success; tone is pragmatic regarding manufacturing scale-up needs.
- Conservatism: Highlights "very conservative" assumptions in Phase III powering (1.5 mL/min benefit vs. observed 4.5 mL/min in Phase II) and acknowledges the aggressive nature of the current timeline.
Miscellaneous:
- Trial Design: Phase III includes 320 patients for accelerated analysis (those receiving at least one injection) and a total population expected to exceed 500 patients for confirmatory analysis.
- Safety Profile: Low dropout rate (<3%) between first and second injections; safety focus on biopsy complications and off-target effects; no unusual SAEs observed in Phase II.
- Mechanism of Action: Paracrine mechanism observed where cells secrete factors into circulation to promote systemic therapeutic response, stabilizing endothelial and epithelial cells.
- Company
- PROKIDNEY CORP
- Keywords
- PROKIDNEY CORP